BofA/Merrill Lynch maintained a Buy rating on Heron Therapeutics (NASDAQ: HRTX) and raised its price target to $54.00 (from $46.00). The change follows positive phase 2 top-line results from HTX-011.

For an analyst ratings summary and ratings history on Heron Therapeutics click here. For more ratings news on Heron Therapeutics click here.

Shares of Heron Therapeutics closed at $33.56 yesterday.

Analyst PT Change

Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results September 23, 2015 11:00 AM Leerink Boosts PT on Heron Therapeutics (HRTX) to $57 Following HTX-011 Phase 2 Top-Line ResultsSeptember 23, 2015 6:50 AM Heron Therapeutics (HRTX) PT Lifted to $58 at Jefferies Following Positive DataSeptember 23, 2015 6:46 AM Heron Therapeutics (HRTX) Announces HTX-011 Phase 2 Met Primary, Secondary Endpoints in Post-Operative PainSeptember 22, 2015 4:07 PM Heron Therapeutics (HRTX) Announces Top-Line Results From Phase 2 Study of HTX-011 in Post-Operative PainSeptember 22, 2015 4:06 PM Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative PainSeptember 22, 2015 4:05 PM